Send to

Choose Destination
Euro Surveill. 2018 Jun;23(25). doi: 10.2807/1560-7917.ES.2018.23.25.1700796.

Resurgence risk for measles, mumps and rubella in France in 2018 and 2020.

Author information

Interuniversity Institute for Biostatistics and statistical Bioinformatics, Hasselt University, Hasselt, Belgium.
Lille University, EA2694 - Santé Publique: Epidémiologie et Qualité des Soins, Lille, France.
Médecine Interne et Maladies Infectieuses, CHU de Poitiers, Poitiers, France.
University of New South Wales, Faculty of Medicine, School of Public Health and Community Medicine, Sydney, Australia.
Centre for Health Economics Research & Modelling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
CHU Lille, Direction de la Recherche en Santé, Lille, France.


BackgroundLarge measles and mumps outbreaks recently occurred throughout Europe and the United States. Aim: Our aim was to estimate and map the risk of resurgence for measles, mumps and rubella in France. Methods: We used a multi-cohort model combining seroprevalence information, vaccine coverage and social contact data. Results: The overall outbreak risk for France in 2018 was highest for mumps, remained significant for measles despite a recent measles outbreak and was low for rubella. Outbreak risks were heterogeneous between departments, as the effective reproduction numbers for 2018 ranged from 1.08 to 3.66. The seroprevalence, and therefore the risk of measles and rubella infection, differed significantly between males and females. There was a lower seroprevalence, and therefore a higher risk, for males. Infants of less than 1 year would be seriously affected in a future outbreak of measles, mumps or rubella, but the highest overall caseload contribution would come from teenagers and young adults (10-25 years old). Conclusions: The high risk for teenagers and young adults is of concern in view of their vulnerability to more severe measles, mumps and rubella disease and complications.


measles; measles-mumps-rubella (MMR) vaccine; modelling; mumps; outbreaks; rubella

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center